Counter-intuitive as it may be, investing in areas that pharma is abandoning could yield great returns for investors. Just look at anti-bacterials in the ’90s and 2000s, says VC Bruce Booth in a Forbes column. So where should investors be looking today? Neuroscience, heart failure and obesity.
The shortage of cancer drugs that’s plagued hospitals for almost two years now has eased, although not completely, according to cancer doctors.
A recent study by Johns Hopkins researchers brings a reality check to the potential (and the limits) of genome sequencing in predicting disease.
{iframe}http://medcitynews.com/2012/06/morning-read-vc-sees-opportunities-in-areas-where-pharma-is-pulling-back/?utm_source=rss&utm_medium=rss&utm_campaign=morning-read-vc-sees-opportunities-in-areas-where-pharma-is-pulling-back{/iframe}